2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
36
Neoplasms
8
Lung Neoplasms
7
Neoplasm Metastasis
4
Neoplasms by Site
3
Lymphoma, Large-Cell, Anaplastic
3
Hematologic Neoplasms
3
Breast Neoplasms
3
Brain Neoplasms
3
Thyroid Neoplasms
2
Sarcoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Gastrointestinal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Solid Tumors
1
Sexual Dysfunction, Physiological
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Rare Tumour
1
Rare Tumor
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Interventions
alvimopan
5
Irinotecan
4
Oxaliplatin
3
Capecitabine
3
Bevacizumab
3
Surveys and Questionnaires
2
Leucovorin
2
Fluorouracil
2
Drug Therapy
2
Cyclophosphamide
2
Colonoscopy
2
Cetuximab
2
Aspirin
2
repotrectinib
1
pralsetinib
1
pembrolizumab
1
napabucasin
1
lutetium Lu 177 dotatate
1
guadecitabine
1
encorafenib
1
copper dotatate CU-64
1
alectinib
1
Ursodeoxycholic Acid
1
Surgical Procedures, Operative
1
Pemetrexed
1
Oviposition
1
Ocoxin
1
Lutetium-177
1
Lutetium
1
Low Density Lipoprotein Receptor-Related Protein-1
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Intestinal Diseases
×
alectinib
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts